This article is more than 5 years old. Information may no longer be current.
Altaire recalls top July ophthalmology news
Click Here to Manage Email Alerts
Altaire Pharmaceuticals issued a widespread recall of ophthalmic products in early July and added to that list in the following weeks, pulling generic products from Walmart, Walgreens and CVS and products sold by other companies.
The articles regarding the recalls posted on Healio.com/OSN were two of the most-read items of the month.
Here are the top five ophthalmology-related articles in July:
Altaire issues large ophthalmic product recall
Some products are manufactured and labeled for exclusive sale at Walgreens, Walmart and CVS, while others are manufactured and labeled for Perrigo Company PLC. Read more.
FDA accepts application for Bimatoprost Sustained-Release
Data supporting the application from the two phase 3 ARTEMIS trials showed Bimatoprost SR reduced IOP by 30% over 12 weeks. In addition, more than 80% of patients were treatment-free after three Bimatoprost SR treatments and did not require further treatment for IOP control for at least 12 months. Read more.
New drug application for Brilliant Blue G solution accepted
If approved, Brilliant Blue G, intended to stain and distinguish the internal limiting membrane from the retina to facilitate removal, will be the first FDA-approved product for this indication. Read more.
Dextenza launches in US
Ocular Therapeutix has commercially launched Dextenza in the United States for the treatment of ocular inflammation and pain after ophthalmic surgery. Read more.
Altaire expands ophthalmic product recall
Altaire Pharmaceuticals is recalling prescription and over-the-counter drugs sold by OCuSOFT, as well as OTC products sold by Accutome, Focus Laboratories, Grandall Distributing Co. Inc., Prestige Brands Inc., Natural Ophthalmics and TRP Company, Inc. Read more.